Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease

  • Martínez-Sánchez, Celia
  • Bassegoda, Octavi|||0000-0002-6036-6026
  • Deng, Hongping
  • Almodóvar, Xènia
  • Ibarzabal, Ainitze|||0000-0002-1220-6474
  • de Hollanda, Ana|||0000-0001-9114-8614
  • Martínez García de la Torre, Raquel-Adela
  • Blaya, Delia
  • Ariño, Silvia
  • Jiménez-Esquivel, Natalia
  • Aguilar-Bravo, Beatriz
  • Vallverdú, Julia
  • Montironi, Carla|||0000-0002-1453-2193
  • Osorio-Conles, Oscar
  • Fundora Suarez, Yiliam|||0000-0003-4950-6988
  • Sánchez Moreno, Francisco Javier
  • Gómez-Valadés, Alicia G.
  • Aguilar-Corominas, Laia
  • Soria, Anna|||0000-0001-5671-8343
  • Pose, Elisa|||0000-0002-0224-7686
  • Juanola, Adrià|||0000-0003-4832-5130
  • Cervera, Marta
  • Perez, Martina
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Affò, Silvia
  • Swanson, Kelly S.
  • Ferrer-Fàbrega, Joana
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Sancho-Bru, Pau|||0000-0001-5569-9259
  • Vidal, Josep|||0000-0002-4564-4518
  • Ginès, Pere|||0000-0003-4657-4504
  • Smith, Andrew M.
  • Graupera, Isabel|||0000-0001-9170-9784
  • Coll, Mar|||0000-0003-3726-0087
: The accumulation of adipose tissue macrophages (ATMs) in obesity has been associated with hepatic injury. However, the contribution of ATMs to hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD) remains to be elucidated. Herein, we investigate the relationship between ATMs and liver fibrosis in patients with patients with NAFLD and evaluate the impact of modulation of ATMs over hepatic fibrosis in an experimental non-alcoholic steatohepatitis (NASH) model. Adipose tissue and liver biopsies from 42 patients with NAFLD with different fibrosis stages were collected. ATMs were characterised by immunohistochemistry and flow cytometry and the correlation between ATMs and liver fibrosis stages was assessed. Selective modulation of the ATM phenotype was achieved by i.p. administration of dextran coupled with dexamethasone in diet-induced obesity and NASH murine models. Chronic administration effects were evaluated by histology and gene expression analysis in adipose tissue and liver samples. In vitro crosstalk between human ATMs and hepatic stellate cells (HSCs) and liver spheroids was performed. Patients with NAFLD presented an increased accumulation of pro-inflammatory ATMs that correlated with hepatic fibrosis. Long-term modulation of ATMs significantly reduced pro-inflammatory phenotype and ameliorated adipose tissue inflammation. Moreover, ATMs modulation was associated with an improvement in steatosis and hepatic inflammation and significantly reduced fibrosis progression in an experimental NASH model. In vitro, the reduction of the pro-inflammatory phenotype of human ATMs with dextran-dexamethasone treatment reduced the secretion of inflammatory chemokines and directly attenuated the pro-fibrogenic response in HSCs and liver spheroids. Pro-inflammatory ATMs increase in parallel with fibrosis degree in patients with NAFLD and their modulation in an experimental NASH model improves liver fibrosis, uncovering the potential of ATMs as a therapeutic target to mitigate liver fibrosis in NAFLD. We report that human adipose tissue pro-inflammatory macrophages correlate with hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD). Furthermore, the modulation of adipose tissue macrophages (ATMs) by dextran-nanocarrier conjugated with dexamethasone shifts the pro-inflammatory phenotype of ATMs to an anti-inflammatory phenotype in an experimental murine model of non-alcoholic steatohepatitis. This shift ameliorates adipose tissue inflammation, hepatic inflammation, and fibrosis. Our results highlight the relevance of adipose tissue in NAFLD pathophysiology and unveil ATMs as a potential target for NAFLD.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

  • Rodríguez-Agudo, Rubén
  • González-Recio, Irene
  • Serrano-Maciá, Marina
  • Bravo, Miren
  • Petrov, Petar D.
  • Blaya, Delia
  • Herranz, José María
  • Mercado-Gómez, María
  • Rejano-Gordillo, Claudia María
  • Lachiondo-Ortega, Sofía
  • Gil-Pitarch, Clàudia
  • Azkargorta, Mikel
  • Liempd, Sebastiaan Martijn van
  • Martínez-Cruz, Luis Alfonso
  • Simão, A. L.
  • Elortza, Félix
  • Martín, César
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Delgado, Teresa C.
  • Argemi, Josepmaria
  • Bataller, Ramón
  • Schoonjans, Kristina
  • Banales, Jesús M.
  • Castro, Rui E.
  • Sancho-Bru, Pau
  • Ávila, Matías A.
  • Julve, Josep
  • Jover, Ramiro
  • Mabe, Jon
  • Simón, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Martínez-Chantar, María Luz
© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background & Aims] Current therapies for the treatment of alcohol-related liver disease (ALD) have proven largely ineffective. Patients relapse and the disease progresses even after liver transplantation. Altered epigenetic mechanisms are characteristic of alcohol metabolism given excessive acetate and NAD depletion and play an important role in liver injury. In this regard, novel therapeutic approaches based on epigenetic modulators are increasingly proposed. MicroRNAs, epigenetic modulators acting at the post-transcriptional level, appear to be promising new targets for the treatment of ALD., [Methods] MiR-873-5p levels were measured in 23 liver tissue from Patients with ALD, and GNMT levels during ALD were confirmed using expression databases (transcriptome n = 62, proteome n = 68). High-resolution proteomics and metabolomics in mice following the Gao-binge model were used to investigate miR-873-5p expression in ALD. Hepatocytes exposed to 50 mM alcohol for 12 h were used to study toxicity. The effect of anti-miR-873-5p in the treatment outcomes of ALD was investigated., [Results] The analysis of human and preclinical ALD samples revealed increased expression of miR-873-5p in the liver. Interestingly, there was an inverse correlation with NNMT, suggesting a novel mechanism for NAD depletion and aberrant acetylation during ALD progression. High-resolution proteomics and metabolomics identified miR-873-5p as a key regulator of NAD metabolism and SIRT1 deacetylase activity. Anti-miR-873-5p reduced NNMT activity, fuelled the NAD salvage pathway, restored the acetylome, and modulated the levels of NF-κB and FXR, two known SIRT1 substrates, thereby protecting the liver from apoptotic and inflammatory processes, and improving bile acid homeostasis., [Conclusions] These data indicate that targeting miR-873-5p, a repressor of GNMT previously associated with NAFLD and acetaminophen-induced liver failure. is a novel and attractive approach to treating alcohol-induced hepatoxicity., [Impact and implications] The role of miR-873-5p has not been explicitly examined in the progression of ALD, a pathology with no therapeutic options. In this study, inhibiting miR-873-5p exerted hepatoprotective effects against ALD through rescued SIRT1 activity and consequently restored bile acid homeostasis and attenuated the inflammatory response. Targeting hepatic miR-873-5p may represent a novel therapeutic approach for the treatment of ALD., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001136-S)., This work was supported by grants from Ministerio de Ciência, Innovación y Universidades MICINN: PID2020-117116RB-I00 CEX2021-001136-S integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER (to MLM-C); Ministerio de Ciência e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (to MLM-C); Instituto de Salud Carlos III, Proyectos Investigación en Salud DTS20/00138 (to MLM-C); La Caixa Scientific Foundation (HR17-00601) (for REC, MLM-C and JMB); La Caixa Consortium (to JMB, REC, KS and MLM-C); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by the European Union, PI20/00690, PI20/00765, PI20/01663 and PI21/00922 (to RJ, PS-B, JA and JMB respectively); Miguel Servet Programme CPII19/00008 (to JMB); AMMF-The Cholangiocarcinoma Charity (EU/2019/AMMFt/001) (to JMB); PSC Partners US and PSC Supports UK 06119JB (to JMB); European Union’s Horizon 2020 Research and Innovation Program, 825510 (for JMB) Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (Madrid, Spain) grant PI21/00770 (for JJ), Fundação para a Ciência e a Tecnologia (grants PTDC/MED-PAT/31882/2017 and EXPL/MED-OUT/1317/2021 to REC and ALS)., Peer reviewed